Some patients advocates and physicians have shown a lot of excitement for Opdivo's results, said Bristol-Myers Squibb CEO Giovanni Caforio.
Bristol-Myers' stock was up 3.33 percent to $66.76 during midday trading hours on Monday, after a sharp drop on Friday following the announcement of the trial results of Opdivo.
The results showed that Opdivo, which is used to treat lung cancer, wasn't effective for all levels of the condition.
"We are very focused on ensuring that our patients have access to our medicines," said Caforio during his first interview as CEO with CNBC. "They prolong survival. Just think about four years ago. There was really no hope for patients with melanoma."
"It really positions Opdivo as a foundational drug in lung cancer, melanoma, and the data is really exciting. We've shown that in some patients with non-squamous lung cancer, which is the most common form of the disease, Opdivo doubles survival. That's unprecedented data."